Open AccessSeverity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
Author(s) -
Jin Yeong Hong,
JaeHoon Ko,
Jinyoung Yang,
Soyoung Ha,
Eliel Nham,
Kyungmin Huh,
Sun Young Cho,
Cheol-In Kang,
Doo Ryeon Chung,
Jin Yang Baek,
You Min Sohn,
Hyo Jung Park,
Beomki Lee,
Hee Jae Huh,
EunSuk Kang,
Gee Young Suh,
Chi Ryang Chung,
Kyong Ran Peck
Publication year - 2022
Publication title -
yonsei medical journal/yonsei medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.702
H-Index - 63
eISSN - 1976-2437
pISSN - 0513-5796
DOI - 10.3349/ymj.2022.63.5.430
Subject(s) - tocilizumab , medicine , dexamethasone , clinical endpoint , dosing , convalescence , gastroenterology , clinical trial , disease
Real-world experience with tocilizumab in combination with dexamethasone in patients with severe coronavirus disease (COVID-19) needs to be investigated.